WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
AUKUS Pillar Two: Defence Minister Judith Collins meets with top US military contractorFire kills 29 people at Istanbul nightclub during daytime renovationsUS Senators Express Concern Over North KoreaSenior US diplomat suggests AUKUS will deter any China moves against TaiwanTens of thousands turn out for King Frederik's successionDunedin dog safety programme aims to keep tails waggingSenior US diplomat suggests AUKUS will deter any China moves against TaiwanHow endangered dolphins could shut down the SailGPDepartment of Conservation 'spread too thin', Penny Nelson tells select committeePublic submissions on proposed anti